Mediastinal Grey Zone Lymphoma From the LYSA
- Conditions
- Mediastinal Grey Zone Lymphoma
- Registration Number
- NCT03037177
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 99
- cases with an intermediate morphology and phenotype between CHL and PMBCL were included after central pathological review
- Cases of CHL with partial CD20 expression or low expression in tumoral cells were excluded and considered as CD20-positive CHL
- Exclusion of sequential form patients (with a diagnostic biopsy of PMBCL and a relapse biopsy of CHL or vise-versa) as they represent a biases for statistical analysis.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EFS in the global population of GZL EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre hospitalier Lyon sud
🇫🇷Pierre Bénite, Rhône Alpes, France